行情

AGEN

AGEN

安帝君斯
NASDAQ

实时行情|Nasdaq Last Sale

2.670
-0.280
-9.49%
盘后: 2.650 -0.02 -0.75% 16:13 02/27 EST
开盘
2.920
昨收
2.950
最高
2.990
最低
2.650
成交量
217.14万
成交额
--
52周最高
4.570
52周最低
2.135
市值
3.67亿
市盈率(TTM)
-2.7231
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGEN价格均价为5.50,最高价位6.00,最低价为5.00。

EPS

AGEN 新闻

更多
  • Agenus A Buy For Cancer Therapy Pipeline
  • Seeking Alpha - Article · 1天前
  • Agenus (AGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
  • Zacks · 6天前
  • Here's Why Agenus Tumbled Today
  • MotleyFool.com · 02/20 21:04
  • UPDATE: Agenus Says Is On Track To Submit 2 Biologics License Applications For Balstilimab, Zalifrelimab In 2020
  • Benzinga · 02/20 14:58

所属板块

生物技术和医学研究
-3.79%
制药与医学研究
-3.00%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

AGEN 简况

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
展开

微牛提供Agenus Inc(NASDAQ-AGEN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGEN股票新闻,以帮助您做出投资决策。